Vincerx Showcases Three Studies at AACR 2024 Annual Meeting

Vincerx Pharma, a biopharmaceutical firm focused on cancer therapeutics, conducted a virtual event for investors. The occasion aimed to showcase preliminary data from Phase 1 trials of their innovative small molecule-drug conjugate (SMDC), VIP236. The company also presented three posters at the AACR Annual Meeting in San Diego from April 5 to 10, where they discussed the VersAptx™ bioconjugation platform and shared clinical findings for VIP236.

The drug has been administered to 20 patients with advanced or metastatic solid tumors under different dosing schedules, and the preliminary outcomes regarding safety, efficacy, and pharmacokinetics will be summarized.
The virtual event, which will include company leadership and industry experts, will be streamed live, with details available on the Vincerx website's Investor Calendar from March 27. A recording will be accessible post-event.
The AACR meeting will feature presentations by Vincerx on various topics, including the activity of VIP943 on AML patient cells, advancements in antibody-drug conjugate (ADC) technology, and challenges in drug metabolism and pharmacokinetics for SMDCs. Each presentation will be led by a representative from the company.
VIP236, a novel SMDC from the VersAptx Platform, is designed to target tumors expressing αvβ3 and has shown promising preclinical results. It is currently in a Phase 1 trial for patients with advanced or metastatic solid tumors. VIP943, another ADC from the same platform, targets CD123 and is in a Phase 1 trial for patients with certain types of leukemia.
The VersAptx Platform is highlighted for its flexibility in developing customized bioconjugates to address various cancer types. Vincerx Pharma, based in Palo Alto with a research facility in Germany, is dedicated to creating novel cancer treatments and has a robust pipeline of products in various stages of development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!